---
layout: default
title: Abemaciclib
parent: 僅模型預測 (L5)
nav_order: 14
evidence_level: L5
indication_count: 0
---

# Abemaciclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABEMACICLIB: Drug Repurposing Evaluation Report

## One-Sentence Summary

Abemaciclib is a selective CDK4/6 inhibitor, originally developed for the treatment of HR-positive, HER2-negative breast cancer (brand name: Verzenio).
The TxGNN model has **not yet generated any predicted new indications** for this drug,
and there are currently **no clinical trials or publications** linked to a repurposing hypothesis in this evidence pack.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in evidence pack (known: HR+/HER2− breast cancer) |
| Predicted New Indication | — None predicted |
| TxGNN Prediction Score | — N/A |
| Evidence Level | L5 (No model prediction or supporting studies available) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on publicly known information, Abemaciclib (DB12001) is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6, it prevents phosphorylation of the retinoblastoma protein (Rb), halting cell cycle progression from G1 to S phase. This mechanism is particularly relevant in cancers driven by dysregulated CDK4/6–cyclin D–Rb signalling, most notably HR-positive, HER2-negative breast cancer.

No new indications have been predicted by TxGNN at this time. Without a target disease, it is not possible to evaluate mechanistic plausibility for repurposing. The absence of a prediction may reflect insufficient data in the knowledge graph, or that Abemaciclib's pharmacological profile did not meet the model's threshold for any novel indication in this run.

To enable a meaningful repurposing evaluation, the TxGNN prediction pipeline should be re-run once the knowledge graph is enriched with Abemaciclib's complete target, pathway, and indication data.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in the evidence pack for a repurposing indication.

---

## Literature Evidence

Currently no related literature available in the evidence pack for a repurposing indication.

---

## Taiwan Market Information

Abemaciclib is **not currently marketed in Taiwan** and holds **0 TFDA authorizations**. No license records are available.

---

## Cytotoxicity

Abemaciclib is an antineoplastic agent (CDK4/6 inhibitor class). The following information is based on the known pharmacological profile:

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | High — neutropenia is the most common Grade ≥3 adverse event; thrombocytopenia also reported |
| Emetogenicity Classification | Low to moderate (diarrhoea is more clinically significant than emesis) |
| Monitoring Items | CBC with differential (every 2 weeks for first 2 months, then monthly), liver function tests (ALT, AST, bilirubin), renal function, signs of venous thromboembolism and interstitial lung disease |
| Handling Protection | Standard oral anticancer drug handling; not a conventional cytotoxic — no special closed-system transfer device required, but follow institutional oral hazardous drug policies |

---

## Safety Considerations

Safety data (key warnings, contraindications, and drug-drug interactions) was not available in the evidence pack for Abemaciclib.

> Please refer to the package insert for safety information. Key known concerns from global labelling include: diarrhoea (dose-limiting toxicity), neutropenia, hepatotoxicity, venous thromboembolism, and interstitial lung disease/pneumonitis. Abemaciclib is a CYP3A4 substrate — concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) require dose reduction.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No new indication has been predicted by TxGNN, and the evidence pack contains critical data gaps (MOA, TFDA package insert warnings, original indication mapping). Without a repurposing hypothesis, there is no actionable evaluation to advance.

**To proceed, the following is needed:**
- **Re-run TxGNN prediction** with enriched knowledge graph data for Abemaciclib (targets: CDK4, CDK6; pathways: Rb/E2F cell cycle control)
- **Fill MOA data gap** (DG002): Query DrugBank API for complete mechanism of action, targets, and pathway information
- **Fill TFDA safety data gap** (DG001): Download and parse TFDA package insert PDF for warnings and contraindications — this is a **blocking** gap for Stage 1 safety assessment
- **Confirm Taiwan regulatory status**: Verify whether Abemaciclib (Verzenio) has pending TFDA applications or is available through special import programmes
- Once a predicted indication is available, re-generate this report with full evidence assessment
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

